Nontuberculous Mycobacterial Infection Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $14.25 billion in 2024 to $15.11 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $19.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is set to drive the growth of the nontuberculous mycobacterial infection market in the future. COPD, a chronic respiratory ailment characterized by persistent and often progressive lung airflow limitation, is closely linked to nontuberculous mycobacterial (NTM) infections, resulting in a more pronounced decline in forced expiratory volume in one second (FEV1) and an elevated exacerbation rate. The weakened immune system and lung tissue damage caused by COPD make it more susceptible to NTM bacterial lung infections. For example, as of March 2023, The Scottish Public Health Observatory (ScotPHO), a public health body in Scotland, reported a rise in COPD rates from 2021 to 2022, with male rates increasing from 83.2 to 97.6 per 100,000 individuals, and female rates rising from 72.6 to 97.3. Consequently, the burgeoning prevalence of chronic obstructive pulmonary disease (COPD) propels the nontuberculous mycobacterial infection market's growth.

The growing prevalence of infectious diseases is expected to drive the expansion of the nontuberculous mycobacterial (NTM) infection market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, that can be transmitted between individuals, leading to a range of symptoms and health complications. As the incidence of infectious diseases, including those that can lead to NTM infections, rises, the market for NTM infections may experience growth. This is due to increased awareness of these infections, leading to more frequent diagnostic testing, earlier detection, enhanced research and development for NTM treatments, and a higher demand for therapies targeting NTM pathogens as healthcare attention on infectious diseases intensifies. For example, in November 2024, the United Nations International Children's Emergency Fund (UNICEF), a US-based intergovernmental organization, reported that pneumonia was the leading infectious disease responsible for the deaths of over 700,000 children annually, equating to around 2,000 deaths per day. Therefore, the rising prevalence of infectious diseases is driving the growth of the NTM infection market.

Leading companies in the nontuberculous mycobacterial (NTM) infection market are adopting new treatment approval strategies, such as Fast Track designation for drug approvals, to maintain their market position. The Fast Track designation, granted by the FDA, is a process that accelerates the development and review of drugs intended for serious conditions with unmet medical needs. For example, in July 2022, the U.S.-based Food and Drug Administration (FDA) granted Fast Track Designation to NUZYRA for the treatment of NTM lung disease caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is an innovative broad-spectrum antibiotic developed to fight serious bacterial infections, including those caused by resistant strains. This designation helps speed up the development and review process for NUZYRA, addressing critical unmet medical needs.

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, entered into a partnership with TB Alliance with the goal of developing telacebec, a drug for the treatment of tuberculosis and other nontuberculous mycobacterial (NTM) infections. The partnership grants TB Alliance the exclusive global license for Telacebec. This signifies that TB Alliance will have the authority to continue its work on the medicine and market it on an international scale. TB Alliance, a South Africa-based non-profit organization, is dedicated to developing and delivering cost-effective TB medications.

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nontuberculous mycobacterial infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than Mycobacterium tuberculosis, which is responsible for tuberculosis (TB). NTM infections are primarily significant due to their impact on human health and their interaction with the immune system.

The primary classes of drugs used to treat nontuberculous mycobacterial infections include macrolides, rifampin, aminoglycosides, and others. Macrolides are a class of antibiotics commonly employed in the treatment of various bacterial infections. These drugs can be administered through different routes, including oral, parenteral (injectable), and others, and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The nontuberculous mycobacterial infection market research report is one of a series of new reports that provides nontuberculous mycobacterial infection market statistics, including nontuberculous mycobacterial infection industry global market size, regional shares, competitors with a nontuberculous mycobacterial infection market share, detailed nontuberculous mycobacterial infection market segments, market trends and opportunities and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. This nontuberculous mycobacterial infection market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.